194 patents
Page 10 of 10
Utility
Universal Donor Cells
11 Mar 20
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania
Filed: 5 Sep 19
Utility
Universal Donor Cells
11 Mar 20
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania
Filed: 5 Sep 19
Utility
Methods and Compositions for Treating Cancer
26 Feb 20
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Mary-Lee DEQUÉANT, Zinkal Samir PADALIA
Filed: 9 May 19
Utility
Materials and Methods for Treatment of Early Onset Parkinson's Disease (PARK1) and Other Synuclein, Alpha (Snca) Gene Related Conditions or Disorders
5 Feb 20
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with SNCA whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 15 Feb 18
Utility
Compositions and Methods for Genomic Editing by Insertion of Donor Polynucleotides
5 Feb 20
The present disclosure provides donor polynucleotides, genome editing systems, methods, and kits which correct or induce a mutation in a gDNA.
Troy Dean CARLO, Roman Lvovitch BOGORAD
Filed: 27 Jun 19
Utility
Materials and Methods for Treatment of Glycogen Storage Disease Type 1A
18 Dec 19
The present application provides materials and methods for treating a patient with Glycogen Storage Disease type la (GSD1a) both ex vivo and in vivo.
Chad Albert COWAN, Roman Lvovitch BOGORAD, Ante Sven LUNDBERG, Kirsten Leah BEAUDRY
Filed: 6 Nov 16
Utility
Materials and Methods for Treatment of Duchenne Muscular Dystrophy
11 Dec 19
The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo.
Ami Meda KABADI, Chad Albert COWAN, Ante Sven LUNDBERG
Filed: 27 Oct 16
Utility
Materials and Methods for Treatment of Dystrophic Epidermolysis Bullosa (Deb) and Other Collagen Type VII Alpha 1 Chain (COL7A1) Gene Related Conditions or Disorders
4 Dec 19
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with COL7A1 whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 13 Feb 18
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
4 Dec 19
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 3 Jun 19
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
4 Dec 19
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 5 Jun 19
Utility
Methods and Compositions for Efficient Gene Deletion
27 Nov 19
Provided herein are gene-editing methods and compositions for improving the efficiency of deleting segments of DNA from cells, cells that are genetically modified using the disclosed methods and compositions, and methods of treatment using the genetically modified cells.
ELIZABETH PAIK, MAURICIO CORTES
Filed: 23 May 19
Utility
Materials and Methods for Treatment of Amyotrophic Lateral Sclerosis (Als) and Other Related Disorders
30 Oct 19
The present disclosure provides materials and methods for treating a patient with one or more conditions associated with SOD1 whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 14 Jun 17
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
16 Oct 19
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
Filed: 6 Jun 19
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
16 Oct 19
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
Filed: 6 Jun 19